Whitehawk (WHWK) Director Vijay K. Iyengar Receives 76,080-Share Award

What Happened Vijay K. Iyengar, a director of Whitehawk Therapeutics, was granted a derivative equity award covering 76,080 shares (reported as acquired at $0.00) on September 9, 2026. The award is reported on Form 4 as an "A" (grant/award) and carries no immediate cash value in the filing. This is a compensation-related grant (not an open-market purchase or sale).

Key Details

• Transaction date: September 9, 2026; filing date: September 11, 2026 (filed within the typical two‑business‑day window).
• Amount: 76,080 shares (derivative award) reported at $0.00 per share; total reported value $0 in the filing.
• Vesting: Subject to continued service; 1/36 of the shares vest monthly beginning on the grant date, with full vesting on the three‑year anniversary (grant date = Sept 9, 2026).
• Post-transaction share ownership: Not disclosed in this filing.
• No 10b5-1 plan, tax‑withholding, or immediate sale noted in the filing.

Context This is a standard director compensation award (an option-like derivative with a three-year monthly vesting schedule). It does not represent an open‑market buy or sale and does not by itself indicate insider buying or selling sentiment. The filing appears timely based on the reported dates.